Syndexa Pharmaceuticals focuses on discovery and development of a new generation of small‑molecule drugs targeting novel mechanisms of endoplasmic reticulum (ER) dysfunction. Its core programs are ER‑modulating compounds currently in preclinical development aimed at indications including metabolic and inflammatory diseases, cardiovascular diseases, and neurodegenerative disorders. The company plans to use new capital to progress these compounds toward development‑candidate selection and to validate the therapeutic potential of its most promising molecules across various indications of ER dysfunction. Syndexa was founded by scientists from Harvard University and is led by President and CEO Teo Uysal. The company is based in Watertown, MA. To date Syndexa has raised $24.8M of equity capital.

Total raised

$1M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2012